Released Apr 15, 2022, after the close
10-K filed Apr 15, 2022, 105 days after period end · 0001140361-22-014764
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$7.95M-$7.95M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$8,522,000N/M
Operating Cash Flowderived-$6,832,000N/M
Free Cash Flowderived-$6,979,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $1.18M | $5.17M | $5.92M |
| Net Income | -$7.95M | -$2.22M | -$1.29M | $52.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR